Skip to Content

Join the 'Docetaxel' group to help and get support from people like you.

Docetaxel News

Treatment Costs Can Be Another Blow to Cancer Patients

Posted 27 Jul 2017 by Drugs.com

THURSDAY, July 27, 2017 – The emotional and physical costs of cancer can be staggering. But the financial side of cancer is also a great burden, with many patients in the United States struggling to pay for treatment, new research reveals. "The current health law has greatly improved access to meaningful health coverage for cancer patients, survivors and all those with chronic diseases," Chris Hansen, president of the American Cancer Society Cancer Action Network, said in a network news release. "Yet costs remain a challenge for those facing cancer. Our country and our lawmakers should come together to find bipartisan solutions that begin to address patient costs without sacrificing the quality of coverage," he urged. Researchers surveyed financial navigators at 11 hospitals in nine states. Financial navigators – typically trained social workers or nurses – help cancer patients ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Breast Cancer, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Anastrozole, Brain Tumor, Letrozole, Tarceva, Megestrol

Doctors' Group Offers Ideas for Easing Cancer Costs

Posted 19 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money woes. The proposals include allowing Medicare to negotiate drug prices, legalizing the importation of drugs, and adopting bundled, or group, payment programs. In the new policy statement, ASCO also says it supports creation of a panel of "stakeholders" in health care to determine the effectiveness of its proposals. Such a group might also outline a uniform approach for assessing the value of drugs. "In what, undoubtedly, is one of the most difficult times in their lives, individuals with cancer should be focused on getting the best care possible, not worrying about financial strain on their families," said Dr. Clifford Hudis. He's CEO of ASCO, a leading ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Femara, Lupron Depot, Gleevec, Lung Cancer, Colorectal Cancer, Votrient, Anastrozole, Brain Tumor, Letrozole

FDA Clears Expanded Use of Cooling Cap to Reduce Hair Loss During Chemotherapy

Posted 6 Jul 2017 by Drugs.com

July 3, 2017 – Today, the U.S. Food and Drug Administration cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss (alopecia) during chemotherapy. This is the first cooling cap cleared by the agency for use in cancer patients with solid tumors. “We are pleased to expand the use of this product for cancer patients with solid tumors to potentially minimize chemotherapy-induced hair loss,” said Binita Ashar, M.D., director, Division of Surgical Devices, in the FDA’s Center for Devices and Radiological Health. “Managing the side effects of chemotherapy is a critical component to overall health and quality of life.” Hair loss is a common side effect of certain types of chemotherapy and is commonly associated with the treatment of most solid tumor cancer. Hair may fall out entirely, gradually, in sections, or may become thin. Hair loss due to cancer treatmen ... Read more

Related support groups: Taxotere, Docetaxel, Solid Tumors, Idamycin PFS, Idarubicin, Docefrez, Idamycin

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Tretinoin, Lupron Depot, Femara, Gleevec, Rituxan, Lung Cancer, Isotretinoin, Colorectal Cancer

Half Report Severe Side Effects From Breast Cancer Therapy

Posted 24 Jan 2017 by Drugs.com

TUESDAY, Jan. 24, 2017 – About half of early stage breast cancer patients experience severe side effects from their treatment, a new study finds. "It's in patients' best interest to receive their treatments on time and on schedule, whenever possible, to give them the best possible outcome," said study author Dr. Steven Katz. He's professor of health management and policy at the University of Michigan. "Unscheduled care for toxicities [side effects] – including clinic visits, emergency department visits and hospital stays – are expensive, inconvenient and disruptive to both doctors and patients. We need to avoid them whenever possible," Katz said in a university news release. For the study, researchers surveyed almost 2,000 early stage breast cancer patients an average of seven months after diagnosis. The women were asked to rate the severity of seven common treatment side effects: ... Read more

Related support groups: Surgery, Breast Cancer, Fluorouracil, Efudex, Breast Cancer, Metastatic, Carac, Herceptin, Taxol, Breast Cancer - Adjuvant, Taxotere, Carboplatin, Cyclophosphamide, Cytoxan, Breast Cancer, Prevention, Paclitaxel, Doxorubicin, Adriamycin, Fluoroplex, Breast Cancer - Palliative, Surgical Prophylaxis

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Fluorouracil, Tretinoin, Lupron Depot, Femara, Gleevec, Rituxan, Lung Cancer, Isotretinoin, Colorectal Cancer, Votrient

Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula

Posted 30 Dec 2015 by Drugs.com

San Jose, Calif. - December 28, 2015 - Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. Teikoku entered into an exclusive licensing agreement with Eagle Pharmaceuticals Inc. ("Eagle Pharmaceuticals") in October 2015 to market, sell and distribute Docetaxel Injection in the U.S. The main difference, compared to other docetaxel formulations, is that Docetaxel Injection is the first non-alcohol formulation approved in the U.S. Further differentiating it from some of the currently marketed docetaxel formulations is that Teikoku's Docetaxel Injection: Requires no prior dilution with a diluent and is ready to add to the infusion solution; and ... Read more

Related support groups: Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, Gastric Cancer, Docetaxel

Keytruda May Help Fight Tough-to-Treat Lung Cancer

Posted 21 Dec 2015 by Drugs.com

SATURDAY, Dec. 19, 2015 – The immune therapy drug Keytruda (pembrolizumab) may extend the lives of people with advanced lung cancer, a new study finds. Keytruda is commonly used to treat other tumor types, and made headlines recently after it helped former President Jimmy Carter fight off brain cancer. In this study, researchers compared Keytruda to the chemotherapy drug docetaxel in more than 1,000 patients with non-small cell lung cancer. All of the patients were battling tumors that had progressed even after chemotherapy. Non-small cell lung cancer is the leading form of the disease. All of the patients' tumors produced a protein called PD-L1, which can shield the tumor from immune system attack, according to a team led by Dr. Roy Herbst, professor of medicine at Yale University School of Medicine. Among patients with the highest amounts of PD-L1, those who received Keytruda lived ... Read more

Related support groups: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Keytruda, Taxotere, Docetaxel, Docefrez

New Drug May Boost Survival a Bit for Some With Advanced Lung Cancer

Posted 28 Sep 2015 by Drugs.com

SUNDAY, Sept. 27, 2015 – A new study finds that the cancer drug nivolumab (Opdivo) extends the lives of some patients with advanced lung cancer for several months. In a head-to-head comparison, patients treated with nivolumab lived an average of 12.2 months, while patients treated with the chemotherapy drug docetaxel lived an average of 9.4 months, the researchers reported. "It looks like we have a new treatment option for patients with metastatic lung cancer that progresses after standard chemotherapy," said lead researcher Dr. Hossein Borghaei, chief of thoracic medical oncology at Fox Chase Cancer Center in Philadelphia. "Now we have another tool, but we have to learn how to make it better so people can even live longer," he said. The results of this phase 3 trial, which was funded by nivolumab's maker Bristol-Myers Squibb, were to be presented Sunday at the European Cancer Congress ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Opdivo, Taxotere, Nivolumab, Docetaxel, Docefrez, Bronchogenic Carcinoma

Immune-Based Drug Shows Potential Against Another Form of Lung Cancer

Posted 1 Jun 2015 by Drugs.com

SUNDAY, May 31, 2015 – Another study finds that a new immune system-focused drug, called nivolumab, may help treat a common form of lung cancer. On Saturday, a study presented at the annual meeting of the American Society of Clinical Oncology in Chicago found that nivolumab cut patients' risk of death from non-small cell lung cancer (NSCLC) – the most common form of the disease – by 27 percent, compared with patients who received an older drug called docetaxel. Now, a second study to be presented Sunday at the meeting finds nivolumab also boosted one-year survival for patients with a subset of NSCLC, called squamous cell NSCLC. That study is being published simultaneously in the New England Journal of Medicine. Forty-two percent of people with squamous cell NSCLC who got nivolumab were still alive one year later, compared to 24 percent of those who got docetaxel, according to a team ... Read more

Related support groups: Lung Cancer, Opdivo, Taxotere, Nivolumab, Docetaxel, Docefrez

Immune-Based Drug Shows Promise Against Advanced Lung Cancer

Posted 29 May 2015 by Drugs.com

FRIDAY, May 29, 2015 – A new drug appears to harness a person's immune system to fight the most common form of lung cancer, according to new clinical trial findings. The drug, nivolumab, reduced patients' risk of death from non-small cell lung cancer by 27 percent compared with patients who received docetaxel, a commonly used chemotherapy medication, researchers said. The study results are scheduled for presentation Saturday at the annual meeting of the American Society of Clinical Oncology, in Chicago. Nivolumab – marketed as Opdivo – primarily helps patients whose tumor cells carry a trait that allows their cancer to avoid detection by the immune system. As a result, overall median survival was 12.2 months in the nivolumab group compared to 9.4 months in the docetaxel group, the researchers reported. Also, only one in 10 patients experienced serious side effects with nivolumab, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Opdivo, Taxotere, Nivolumab, Docetaxel, Docefrez

Early Chemo May Boost Survival in Advanced Prostate Cancer

Posted 14 May 2015 by Drugs.com

THURSDAY, May 14, 2015 – Starting the chemotherapy drug docetaxel at the same time as hormone therapy can improve survival for men with newly diagnosed, advanced prostate cancer, British researchers say. Currently, chemotherapy is generally given after hormone therapy stops working. But the new study found that when the two therapies were paired at the start of treatment, patients lived an average of 10 months longer. The combination had even greater benefits for men whose prostate cancer had spread to other parts of their bodies – known as "metastatic" cancer. These men experienced an average 22-month improvement in their overall survival, the findings showed. "We hope our findings will encourage doctors to offer docetaxel to men newly diagnosed with metastatic prostate cancer, if they are healthy enough for chemotherapy," said lead author Dr. Nicholas James, director of the Cancer ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Reclast, Zoladex, Zytiga, Zometa, Taxotere, Eligard, Lupron Depot 3.75 mg, Aclasta, Zoledronic Acid, Xtandi, Supprelin, Leuprolide, Degarelix, Lupron Depot-PED, Firmagon, Trelstar, Docetaxel

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Depo-Provera, Provera, Amoxicillin, Metronidazole, Doxycycline, Clindamycin, Cephalexin, Azithromycin, Penicillin, Methotrexate, Bactrim, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Flagyl, Lupron, Keflex, Medroxyprogesterone

New Guidelines for Treating Advanced Prostate Cancer

Posted 8 Sep 2014 by Drugs.com

MONDAY, Sept. 8, 2014 – Men newly diagnosed with prostate cancer often turn first to testosterone-depleting therapies, since male hormones help prostate tumors grow. But, those therapies almost always fail over time as the tumor develops resistance, according to oncologists. Now, experts are issuing updated guidelines to help patients in this situation decide what to do next. The guidelines, issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada, highlight recent advances in treating this more advanced form of prostate cancer. "We have seen unprecedented progress against advanced prostate cancer recently, with six new treatments approved in the last couple of years," Dr. Ethan Basch, co-chair of the ASCO/CCO panel of experts that developed the guidelines, said in a news release from the two groups. "There are a lot of nuances about ... Read more

Related support groups: Prostate Cancer, Ketoconazole, Zytiga, Casodex, Nizoral, Taxotere, Xtandi, Bicalutamide, Provenge, Docetaxel, Abiraterone, Xofigo, Flutamide, Jevtana, Sipuleucel-t, Radium 223 Dichloride, Nilutamide, Cabazitaxel, Nilandron, Docefrez

FDA Medwatch Alert: Docetaxel: Drug Safety Communication - May Cause Symptoms of Alcohol Intoxication

Posted 24 Jun 2014 by Drugs.com

ISSUE: FDA is warning that the intravenous chemotherapy drug docetaxel contains ethanol, also known as alcohol, which may cause patients to experience intoxication or feel drunk during and after treatment. FDA is revising the labels of all docetaxel drug products to warn about this risk.  BACKGROUND: Docetaxel is a prescription chemotherapy drug used to treat different kinds of cancer, including cancers of the breast, prostate, stomach, head and neck cancers, and non-small-cell lung cancer.  RECOMMENDATION: Health care professionals should consider the alcohol content of docetaxel when prescribing or administering the drug to patients, particularly in those whom alcohol intake should be avoided or minimized and when using it in conjunction with other medications. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these p ... Read more

Related support groups: Cancer, Taxotere, Docetaxel, Docefrez

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Prostate Cancer, Breast Cancer, Breast Cancer, Metastatic, Non-Small Cell Lung Cancer, Solid Tumors, Head and Neck Cancer, Gastric Cancer

Related Drug Support Groups

Taxotere, Docefrez

Docetaxel Patient Information at Drugs.com